Ann: Appendix 4C - Quarterly - 30 June 2023, page-14

More contradicting information:

Under Corporate Update, it states:

"Patrys is entitled to a refund of approximately $2.7 million under the Federal Government’s R&D Tax Incentive Scheme which it expects to receive during 1H FY2024"

but under section 8.6.2, they answer:

"The Company is anticipating a R&D refund to its wholly-owned subsidiary Nucleus Therapeutics Pty Ltd of approximately $2.7 million for the FY23 financial year, and expects to receive this refund before the end of CY 2023...."

So when is the company expected to receive this $2.7m refund, "1H FY2024" or "before end of FY2023" or am I reading this wrong??

This quarterly wreaks of an upcoming CR very, very soon regardless of how the Dr tries to spins this quarterly by using different wording!

Btw, the CDMO should be held accountable for their mess up on the DX1 trial imo!